Since the first immune checkpoint blocker ipilimumab was approved by the US FDA in 2011, more drug companies have sought to develop their own immune therapy drugs.
Watch Now
news-medical
Listen in as Dr Jeremy Day, of the Department of Neurobiology at the University of Alabama at Birmingham, discusses his work exploring non-coding RNA species regulation of DNA methylation in neuronal system- including a review of some of his lab's latest unpublished data.
Watch Now
Questexweb
Patient-centricity gets a lot of buzz, but what are the benefits of involving patients in the planning of a clinical trial?
Watch Now
Charles River
What does the future of your drug discovery program look like? Many industry leaders are finding themselves in uncharted waters: the science is more sophisticated than ever, producing paradigm-altering treatments. But, historically high R&D costs and low success rates has emphasized the need to identify drugs focused on translationally-relevant targets in the most cost and time efficient way.
Watch Now